Furthermore, the combination of terameprocol and everolimus (RAD001) significantly reduced insulin-like growth factor binding protein 2 (IGFBP-2) overexpression and synergistically suppressed endometrial cancer growth [139]. Here, IGFBP2 is linked to endometrial cancer.